Braveheart Bio (BRVE) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.72 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | ETON |
|---|---|---|
| Share price | $19.09 | $54.75 |
| Market cap | $1.72B | $1.56B |
| 1-day change | +2.74% | -0.24% |
| YTD return | — | +224.54% |
| 1-year return | — | +159.48% |
| 5-year return | — | +953.36% |
| P/E ratio (TTM) | — | 136.88 |
| Forward P/E | — | 21.22 |
| EPS (TTM) | $-6.08 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $66.37 |
| 52-week low | $17.86 | $14.27 |
| Distance from 52-week high | -40.34% | -17.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +137.04% | +29.68% |
| Average volume | 562.23K | 606.07K |
| Shares outstanding | 90.04M | 28.58M |
| Employees | 49 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
BRVE vs ETON FAQ
Which is bigger, Braveheart Bio or Eton Pharmaceuticals?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.72B compared with $1.56B for Eton Pharmaceuticals (ETON).
Are Braveheart Bio and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.